ライフサイエンスコーパス: E coli

1 lates (2301 [85%] K pneumoniae and 402 (15%) E coli).

2 terial gel overlay against S epidermidis and E coli.

3 al critical step in the host defense against E coli.

4 with IAV markedly increased phagocytosis of E coli.

5 well as hemostatic system responses to LD100 E coli.

6 the inflammatory cytokine response to LD100 E coli.

7 l ulcer, which was culture positive for ESBL E coli.

8 HEp2 cells and (2) killing of intracellular E coli.

9 dly attenuated when the gene is deleted from E coli.

10 in response to serum-opsonized S aureus and E coli.

11 o produce IL-10 in response to adenosine and E coli.

12 gene arrangement pattern similar to that in E coli.

13 ; difference 7.1%, 95% CI 2.2-10.8, p=0.005; E coli: 3/211, 1%, difference 4.3%, 1.5-5.9, p=0.003).

14 coccus aureus (652, 10%), GBS (326, 5%), and E coli (319, 5%).

15 s were treated with both IAV and unopsonized E coli, a marked enhancement of the rate and extent of n

16 control baboons were also infused with LD100 E coli alone and followed as described above.

17 aneous treatment of neutrophils with IAV and E coli also elicited greater hydrogen peroxide productio

18 Eight baboons infused for 2 hours with LD100 E coli also were given five bolus infusions of DEGR VIIa

19 with apparent transmission of NDM-producing E coli among patients at 1 hospital.

20 nd/or attenuates the lethal effects of LD100 E coli and (2) whether these effects are accompanied by

21 promoter-luciferase construct indicated that E coli and adenosine synergistically activate IL-10 tran

22 alence of resistance from 1992 to 1996 among E coli and all isolates combined to ampicillin (P<.002),

23 The prevalence of resistance among E coli and all isolates combined was more than 20% for a

24 baboons administered a two-hour infusion of E coli and followed for a maximum of 28 days.

25 SBL-containing multiple antibiotic-resistant E coli and K pneumoniae.

26 The prevalence of mcr-1 was investigated in E coli and Klebsiella pneumoniae strains collected from

27 profloxacin hydrochloride was 0% to 2% among E coli and less than 10% among all isolates combined, an

28 eptible clinical isolates of K pneumoniae or E coli and ten susceptible same-species comparator isola

29 e coagulopathic and inflammatory response to E coli and that EPCR provides an additional critical ste

30 an 9% in 1992 to more than 18% in 1996 among E coli, and from 8% to 16% among all isolates combined.

31 , rotavirus, Shigella spp and enteroinvasive E coli, and Vibrio cholerae-the strength of association

32 rees C) and an etiologic organism other than E coli are at high risk for the development of renal sca

33 er p 2/1S were expressed in large amounts in E coli as soluble and folded proteins.

34 Asparaginase levels and antibody to both E coli asparaginase and PEG-asp were measured weekly jus

35 Use of native E coli asparaginase in induction leads to high hypersens

36 s) in intensification after receiving native E coli asparaginase in induction.

37 ations are depleted by conventional doses of E coli asparaginase in the majority of patients, but the

38 Using the double-labeled E coli assay, HPC was decreased in all transplanted anim

39 no effect on the peak TNF response to LD100 E coli at T = 2 hours (170 +/- 32 v 120 +/- 35 ng/mL).

40 th albumin) or an adenovirus encoding either E coli beta-galactosidase (Ad.CMVLacZ, viral control; 10

41 INTERPRETATION: This tetravalent E coli bioconjugate vaccine candidate was well tolerated

42 used in case of clinical hypersensitivity to E coli but not for subclinical development of antibodies

43 C, Cryptosporidium, typical enteropathogenic E coli) can substantially reduce the burden of moderate-

44 Conversely, only E coli challenge activated the complement system, reachi

45 sequestration and vascular injury induced by E coli challenge.

46 y effect of adenosine on IL-10 production by E coli-challenged macrophages, whereas A(2B) receptors h

47 h these bacteria compared with nonpathogenic E coli; chitinase activities were measured using the col

48 to a farm was associated with mcr-1-negative E coli colonisation (p=0.03, univariate test).

49 mpared with 378 patients with mcr-1-negative E coli colonisation, whereas living next to a farm was a

50 f women in the cefpodoxime group had vaginal E coli colonization.

51 Uropathogenic E coli containing prsG-adhesin-encoding plasmids aggluti

52 eceiving blocking mAb to EPCR plus sublethal E coli died 7 to 54 hours after challenge, whereas all a

53 t strain types of resistant K pneumoniae and E coli distributed among the nursing homes.

54 cularly after intracolonic administration of E coli DNA.

55 istration of lysozyme prevented expansion of E coli during maternal separation and visceral hypersens

56 impaired their bactericidal activity against E coli, E faecalis, and S typhimurium, whereas exposure

57 issues from animals receiving only sublethal E coli exhibited none of these abnormal histopathologic

58 E coli-expressed purified domain I selectively bound IgG

59 x2 are more likely to cause D(+)HUS than are E coli expressing only Stx1.

60 The validation of MM-PBSA for the E coli FabI system serves as a platform for inhibitor de

61 ce, has not been previously observed in ESBL E coli from any infection site.

62 at shock proteins IbpA and IbpB that protect E coli from oxidative stress, compared to healthy, wild-

63 to ciprofloxacin rose from 2.5% to 31.1% in E coli, from 1.7% to 70.2% in Klebsiella spp and from 5.

64 We also found that nonpathogenic E coli gain degrading activity when they are forced to e

65 Analysis of the E coli genome showed it to belong to multilocus sequence

66 istant, and primary ocular infection by ESBL E coli has rarely been reported.

67 lin G antibodies, but not anti-human or anti-E coli homologs, was independently associated with CAD.

68 1.9; 0.99-3.5) and typical enteropathogenic E coli (HR 2.6; 1.6-4.1) in infants aged 0-11 months, an

69 es from patients with IBS, larger numbers of E coli HS and S typhimurium passed through the epitheliu

70 P= 0.001, OR 3.9), cHsp10 (P=0.045, OR 3.8), E coli Hsp60 (P=0.04, OR 1.5) and C pneumoniae (P=0.03,

71 group 2 pathogens, particularly S aureus and E coli, in otherwise unexplained cases of SUDI suggests

72 ion in platelets coincubated with pathogenic E coli including alpha-hemolysin producing strains.

73 gene, but not chiA from nonpathogenic (K12) E coli, increased adhesion.

74 onal C3H/HeN adult mice with 10(9) commensal E coli induced visceral hypersensitivity.

75 The stimulatory effect of adenosine on E coli-induced IL-10 production did not require toll-lik

76 e for the stimulatory effect of adenosine on E coli-induced IL-10 promoter activity.

77 Adenosine augmented E coli-induced nuclear accumulation and DNA binding of C

78 py is widely used to treat enteroaggregative E coli infection.

79 olates and a random sample of mcr-1-negative E coli infections from the retrospective collection betw

80 eit with different timing, both FXa/PCPS and E coli infusion led to robust thrombin and plasmin gener

81 , the antimicrobial effect of PGRP-S against E coli is synergistic with lysozyme, and lysozyme and PG

82 or intermediate for 89.2% of ESBL-producing E coli isolates (569/638 isolates) and 67.7% of ESBL-pro

83 tudy, we included 76 mcr-1-positive clinical E coli isolates and 508 mcr-1-negative isolates.

84 We observed mcr-1 carriage in E coli isolates collected from 78 (15%) of 523 samples o

85 ction, mcr-1 was detected in 76 (1%) of 5332 E coli isolates, 13 (<1%) of 348 Klebsiella pneumoniae,

86 cted or colonized with ceftazidime-resistant E coli, K pneumoniae, or both were identified.

87 lly engineered) have intestinal expansion of E coli leading to visceral hypersensitivity.

88 ed resistance to immune clearance in an ESBL E coli lineage already known for its virulence is an uns

89 E coli LPS and human HSP 60 produced similar effects.

90 duction, but it did not alter the ability of E coli LPS to induce these functions.

91 assess the safety of heat-labile toxins from E coli (LT) delivered via patch.

92 gene expression in commensal gut bacterium (E coli NC101).

93 The E coli O-antigen is a promising vaccine target.

94 he evolution and geographical distibution of E coli O157 (and its close pathogenic relatives); the ma

95 Because E coli O157 can survive in the environment for more than

96 Many infections of E coli O157 could be prevented by the more effective app

97 food or beverage sources and the recovery of E coli O157 from the rafters suggest that airborne dispe

98 Case-patients had laboratory-confirmed E coli O157 infection, hemolytic-uremic syndrome, or blo

99 Environmental contamination with E coli O157 may be a public health problem.

100 d 42 weeks after the fair also grew the same E coli O157 strain.

101 ks after the fair grew Shiga toxin-producing E coli O157.

102 Deer can be colonized by E coli O157:H7 and can be a source of human infections.

103 ly determine whether antibiotic treatment of E coli O157:H7 enteritis increases the risk of HUS.

104 eported a series of patients with documented E coli O157:H7 enteritis, some of whom developed HUS; ha

105 sed risk of HUS with antibiotic treatment of E coli O157:H7 enteritis.

106 ate power, with multiple distinct strains of E coli O157:H7 represented, is needed to conclusively de

107 In a subsequent survey, E coli O157:H7 was recovered from 3 (9%) of 32 deer feca

108 E coli O157:H7 with the same distinctive, pulsed-field g

109 We further tested 33 isolates of E coli O157:H7, STEC, Shigella dysenteriae, and nonpatho

110 cherichia coli, in North America principally E coli O157:H7.

111 However, significantly fewer UTIs caused by E coli of any serotype were noted in the vaccine group c

112 sors such as DTT, IFN, and adherent-invasive E coli or control agents; cells were analyzed by immunob

113 A virus infection from patients with either E coli or S pneumoniae infection.

114 uch as enteroaggregative or enteropathogenic E coli or Salmonella).

115 s those produced by Shigella, enteroinvasive E coli, or Clostridium difficile) that damage cells or t

116 ent set of patients with either influenza A, E coli, or S pneumoniae infection.

117 mmunogenic than the native Escherichia coli (E coli) preparation, and can be more feasibly administer

118 lations with either Staphylococcus aureus or E coli, pretreatment with mAb LAM1.3 did not significant

119 ts were colonized with ceftazidime-resistant E coli; prior receipt of ciprofloxacin or trimethoprim-s

120 ence of all five known c-type cytochromes in E coli, providing biochemical evidence that these are cc

121 e plasmid carrying mcr-1 was mobilised to an E coli recipient at a frequency of 10(-1) to 10(-3) cell

122 ransferase enzyme family, with expression in E coli resulting in the addition of phosphoethanolamine

123 scherichia coli, heat-stable enterotoxigenic E coli, rotavirus, Shigella spp and enteroinvasive E col

124 301 K pneumoniae samples and 77 (19%) of 402 E coli samples were carbapenemase (KPC, NDM, OXA-48-like

125 te vaccine containing the O-antigens of four E coli serotypes (ExPEC4V).

126 C binding to EPCR plus sublethal numbers of E coli (SLEC) (n = 4); (2) mAb to EPCR that does not blo

127 imes), and heat-stable enterotoxin-producing E coli ([ST-ETEC] around 1.5 times).

128 The mcr-1 gene in E coli strain SHP45 was identified by whole plasmid sequ

129 When an E coli strain, SHP45, possessing colistin resistance tha

130 variation have focused on laboratory-adapted E coli strains and have been limited in the number of mu

131 The cell-free E coli system offers a platform for rapidly generating i

132 athways may be relevant to understanding why E coli that express Stx2 are more likely to cause D(+)HU

133 Here we report the crystal structures of E coli transcription initiation complexes (TICs) contain

134 onality, and the incidence of UTIs caused by E coli vaccine serotypes in each group.

135 ferent signature discriminated patients with E coli versus S aureus infections with 85% accuracy (34

136 The ratio of K pneumoniae to E coli was 11:1.

137 al inflammatory reaction to inoculation with E coli was attenuated, as quantified by changes in blood

138 ony-forming units per mL of vaccine-serotype E coli was noted in the vaccine compared with the placeb

139 Consecutive clinical isolates of E coli were collected at the Royal London Hospital in 19

140 cts, although apoptotic effects of opsonized E coli were greater.